Condition: Spinal Cord Injury Cervical · Spinal Cord Injury Thoracic · Spinal Cord Injury, Acute · Sponsor: Lineage Cell Therapeutics, Inc.
The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.
This description comes directly from the study's public registry record.
Reference Study ID Number: LCTOPC1-SCI-03 https://lineagecell.com/products-pipeline/opc1/ · 442-287-8940 · ClinicalTrials@lineagecell.com
Always discuss trial participation with your own doctor first.
| Rancho Research Institue | Downey, California, United States | Not Yet Recruiting |
| University of California, San Diego | La Jolla, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06841770